Introduction
Single-sided deafness (SSD) affects the quality of life of patients, since they experience discomfort in difficult situations such as hearing in noise or sound localization [Douglas et al., 2007] . The loss of hearing in one ear suppresses the interaural time and sound level differences that are responsible for localization [Kitterick et al., 2014] . Patients affected by SSD also show the effect of the acous-USA). Nine patients were included in the study. They underwent physical examination, free-field speech audiometry at 40 and 60 dB, a hearing-in-noise test (Hirsch' s test and the squelch test), the Glasgow Benefit Inventory (GBI) questionnaire, and a specific questionnaire on patient satisfaction with Alpha 1. Afterwards, the Alpha 2 external processor was delivered to all patients, and the above-mentioned protocol was repeated after 1 month with the Alpha 2. A statistically significant improvement was found in the speech dis-tic head shadow [Carlile, 2006] , which is the cause of these difficulties [Van Wanrooij and Van Opstal, 2004] . Finally, listening to sounds coming from the impaired side is also challenging for these patients.
Many studies have been carried out in order to define the optimal treatment for this pathological condition. Contralateral rerouting of signal (CROS) hearing aids [Bosman et al., 2003; Finbow et al., 2015; Hol et al., 2005; Wazen et al., 2003 ] and percutaneous bone-anchored hearing devices [Faber et al., 2013; Martin et al., 2010; Stewart et al., 2011; Zeitler et al., 2012] have been proposed for the rehabilitation of SSD with different results. More recently, cochlear implant has been suggested for the rehabilitation of SSD [Arndt et al., 2011; Erbele et al., 2015; van Zon et al., 2015; Vermeire and Van de Heyning, 2009] .
The Sophono Alpha ® system (Sophono, Boulder, Colo., USA) is a transcutaneous bone-conductive hearing device. The major advantage of this system, compared to the percutaneous ones, is the presence of intact skin that dramatically reduces skin-related complications [Wazen et al., 2008] . The use of the Alpha 1 ® system has already been described for conductive or mixed hearing loss in adults and children [Escorihuela-García et al., 2014; Denoyelle et al., 2013; Hol et al., 2013; Magliulo et al., 2015; Siegert and Kanderske, 2013; Sylvester et al., 2013] . The first prospective clinical study comparing the Alpha 1 system to CROS hearing aids in SSD has recently been published [Leterme et al., 2015] . The authors showed that the Alpha 1 was preferred to the CROS in 72% of patients and that hearing performance was significantly improved when using the Alpha 1 system compared to the unaided condition, whereas there were no statistically significant differences when comparing the audiological outcomes of the 2 devices. Recently, the new Sophono Alpha 2 ® external processor has been released. The main differences between the Alpha 1 and the Alpha 2 are the following: -A squarer and smaller shape ( fig. 1 Color version available online -The presence of 2 microphones (instead of 1 omnidirectional); one is directional and one is omnidirectional -Transcutaneous energy transmission technology that should allow obtaining a functional gain of 30 dB by optimizing the mechanical impedance close to skin impedance. It uses an impedance adaptation achieved by the design of the device and the implemented force transducer, which decreases the impedance over the relevant range for speech recognition to the impedance of the skin. This is achieved by two resonance frequencies close to each other in the relevant range flattening the transfer barriers through the skin and matching the resonance behaviors of the device and the skin The aim of this prospective clinical study was to analyze the audiological performance and quality of life of patients affected by SSD who were previously users of the Alpha 1 external processor, when upgrading them to the new Alpha 2 external processor.
Materials and Methods
This prospective clinical study was authorized by the hospital ethics committee, and all patients gave written consent for the use of their clinical data. Collin ® Ltd. (Bagneux, France), a local distributor of the Alpha system, supported this study by providing the Alpha 2 external processor to all patients. The Sophono Alpha system consists of one external processor and one implantable twin magnet ( fig. 1 b, c) . The external processor contains a bone-conductive oscillator which is mounted on two external magnets. The implantable twin magnets are encapsulated in a titanium case which is fixed to the skull with five little arms.
Protocol
Nine patients were included in this study ( table 1 ). All patients had been using the Alpha 1 system for at least 1 year.
At the first visit, a physical examination of the skin over the implant was performed (normal or hyperemic). The strength of the magnet, ranging from 0 to 7, was noted. The strength of the magnet was the lowest strength that allowed the uncoupling of the external device when a strength ranging from 1 to 1.5 N was applied with a specific tool. The total number of hours of wearing the external processor per day was analyzed as well as the regularity of wearing the external processor (every day or occasionally in a particular situation as in a noisy environment, during social activities, etc.).
Audiological Tests
All tests were performed in an audiometric insonorized room. The mean air conduction and bone conduction thresholds were calculated using headphones (the mean of frequencies 500, 1,000, 2,000, and 4,000 Hz). In the free-field test as well as in noise, 3 speakers were used placed at 1 m from the patient (in front and to the left and right ears).
Free-field speech audiometry in quiet using Lafon's monosyllabic words delivered at 40 and 60 dB SPL to the deaf side was carried out, and the percentage of correct responses was noted.
In noise, two tests were performed depending of the respective presentation of the noise and stimulation: Hirsch's test [Hirsch and Anderson, 1980] and the squelch test. Both tests aimed to measure the efficacy of the system for the transfer of sound information to the contralateral side. Hirsch's test was performed using white noise at 65 dB SPL presented frontally and Lafon's monosyllabic words of increasing intensity delivered to the deaf side, and the speech reception threshold (SRT) was noted. The squelch test was done using white noise at 65 dB SPL delivered to the deaf side and monosyllabic words of increasing intensity presented frontally, recording the SRT. All these tests were performed in the unaided condition and with Alpha 1 during the first visit and with Alpha 2 after 1 month.
Questionnaires
Patient satisfaction with Alpha 1 was evaluated during the first visit by the Glasgow Benefit Inventory (GBI) [Robinson et al., 1996] and by a specific questionnaire on patient satisfaction. The GBI was divided into 3 subgroups (general, social support, and physical health), and the results were reported from -100 to +100 for each subgroup and for the global score. The specific questionnaire investigated the satisfaction of wearing the device through a Likert scale ranging from 0 to 4 (0 = very dissatisfied, 1 = somewhat dissatisfied, 2 = neither satisfied nor dissatisfied, 3 = satisfied, and 4 = very satisfied).
Afterwards, the Alpha 2 external processor was delivered to all patients, and the questionnaires described above were repeated after 30 days with the Alpha 2 processor. The same method of fitting was used across patients, and this fitting was normalized with the air conduction pure-tone average as well as the same magnetic strength being maintained between Alpha 1 and Alpha 2. Values are means ± SD (of 500, 1,000, 2,000, and 4,000 Hz). VS = Vestibular schwannoma; SSNHL = sudden sensorineural hearing loss; AC = air conduction; BC = bone conduction; PTA = pure-tone audiometry. 
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Results
Population
There were 5 males and 4 females. The mean age was 50 ± 9.9 years (range 40-65); the right side was involved in 5 cases and the left side in 4 cases. The etiology of unilateral hearing loss was vestibular schwannoma surgery (22%), sudden sensorineural hearing loss (22%), chronic otitis (11.2%) with ipsilateral profound hearing loss, head trauma (11.2%), ototoxicity (11.2%), mumps (11.2%), and congenital hearing loss (11.2%).
At the first visit with the Alpha 1, the local skin over the implant was evaluated as normal in 8 cases and hyperemic in 1 case. The mean strength of the external magnet was 5 ± 1.7 N. The mean wearing time per day was 5 ± 4.5 h, and the patients had regular daily use of the Alpha 1 in 5 cases and occasional use in 4 cases.
With the Alpha 2, the local skin was evaluated as normal in 7 cases and hyperemic in 2 cases. The strength of the external magnet was 5 ± 1.9, and the wearing time was 7 ± 4.3 h, values that were similar to those obtained with the Alpha 1 (McNemar test). One more patient used the Alpha 2 regularly (6 instead of 5 for Alpha 1).
Audiological Tests
The mean air conduction threshold of the contralateral ear was 21 ± 9 dB HL, and the bone conduction threshold was 14 ± 8.6 dB HL ( table 1 ).The mean speech discrimination score ( fig. 2 a) using monosyllabic words delivered at 40 (73%) and 60 dB SPL (98%) was similar in the unaided condition and with Alpha 1. Similarly, no difference in SRT in both Hirsch's test (58 dB) and the squelch test (54 dB) was observed between the unaided condition and with the Alpha 1 ( fig. 2 b) .
At the 1-month audiological tests with Alpha 2, using monosyllabic words at 40 dB SPL, the speech discrimination score was 82 ± 19.7%. The mean gain was 8 ± 8%, and this difference was significant (paired t test, p < 0.005; fig. 2 a) . At 60 dB SPL, the speech discrimination score was 100 ± 0.7% with Alpha 2, a plateau value not different to that observed with Alpha 1. Regarding Hirsch's test ( fig. 2 b) , the SRT with Alpha 2 was similar to that observed with Alpha 1, but it was improved by 4 ± 4 dB (p < 0.02, paired t test) compared to the unaided condition. For the squelch test, the SRT with Alpha 2 improved by 1.4 ± 1 dB (p < 0.02, paired t test) compared to that measured with Alpha 1. Figure 3 shows the speech discrimination score for free-field speech audiometry at 40 dB SPL ( fig. 3 a) and the SRT in both Hirsch's test and the squelch test for all patients ( fig. 3 b, c) .
Questionnaires
The GBI global score with Alpha 1 was 11 ± 12.9, and the scores for the subscales were 12 ± 15.6, 15 ± 22.7, and 6 ± 22.6 for the general, social support, and physical health, respectively ( fig. 4 ) . Patient satisfaction stood at 2 ± 1.2 using the specific questionnaire. Regarding the GBI score, with the use of the Alpha 2 device we obtained a value of 14 ± 11.0 for the global score and 18 ± 18.3, 18 ± 22.7, -4 ± 11.1 for the general, social support, and physical health subscales, respectively. There was no significance when comparing these data to the results with the Alpha 1 processor ( fig. 4 , Wilcoxon  test) . The specific questionnaire revealed a score of 3 ± 0.3 with the Alpha 2, a value not different from that obtained with the Alpha 1 (2 ± 1.2, Wilcoxon test).
Discussion
The SSD certainly represents one of the most difficult clinical conditions for hearing rehabilitation. Studies analyzing the results of bone-anchored hearing aids (BAHA) showed that the hearing outcomes and the patient's satisfaction were significantly poorer in patients affected by SSD than in those affected by conductive or mixed hearing loss [Martin et al., 2010; Tringali et al., 2008] . Furthermore, when using a transcutaneous bone-conductive hearing device, the presence of an intact skin, although beneficial from a clinical point of view, attenuates sound transmission, especially in high frequencies [Kurz et al., 2014; Verstraeten et al., 2009] , and this could decrease the efficiency of this device when used in SSD. The Sophono Alpha system is a bone-conductive transcutaneous implant that transmits the vibrations of the external processor thought an intact skin by means of a magnetic coupling. It was first described by Siegert [2011] , and since then other papers have been published concerning the use of this device in different pathological conditions [Denoyelle et al., 2013; Escorihuela-García et al., 2014; Hol et al., 2013; Leterme et al., 2015; Magliulo et al., 2015; Siegert and Kanderske, 2013; Sylvester et al., 2013] .
The use of the Alpha 1 system has already been described in conductive or mixed hearing loss in adults and children [Denoyelle et al., 2013; Escorihuela-García et al., 2014; Hol et al., 2013; Magliulo et al., 2015; Siegert and Kanderske, 2013; Sylvester et al., 2013; ] . No studies have yet been published in the English literature concerning the use of Alpha 2.
After the release of the new external processor Alpha 2, we aimed to study whether, regardless the technological improvements of this new external processor, there were audiological improvements with the use of this new device compared to the previous Alpha 1.
First of all, the new external processor is safe; no increase in adverse skin reactions was observed. Nevertheless, the results of the GBI questionnaires are similar to those obtained with the use of other bone-anchored hearing devices in SSD [Faber et al., 2013; Saroul et al., 2013] .
From an audiological point of view, as expected, the benefits of Alpha 2 are significant at a stimulation of 40 dB, and this could be useful in improving speech perception of the deaf side. At 65 dB this difference is not significant, probably because at this level of stimulation the normal-hearing ear is stimulated as well. Regarding hearing-in-noise tests, we observed a significant difference for the squelch test; this test reflects the reduced masking of speech by the noise [Snik et al., 2015] , and the improvement is probably due to the presence of the 2 microphones in the Alpha 2 external processor. For Hirsch's test, even if there was an improvement in the scores, this was not significant probably because of the low number of cases. In any case, when compared to the unaided condition, the improvement with Alpha 2 was significant.
In conclusion, the new external processor Alpha 2 improves hearing performance in patients with SSD compared to the previous Alpha 1 external processor. Since this pathological condition is one of the most challenging to rehabilitate, the upgrade proved to be beneficial for the patients.
